Genentech Touts Phase III PEMPHIX Study Results Showing Rituxan Superior to Mycophenolate Mofetil in Patients With Pemphigus Vulgaris.
M2 PHARMA-October 23, 2019-Genentech Touts Phase III PEMPHIX Study Results Showing Rituxan Superior to Mycophenolate Mofetil in Patients With Pemphigus Vulgaris
(C)2019 M2 COMMUNICATIONS
- US-based biotechnology company Genentech has received data from the Phase III PEMPHIX study evaluating the efficacy and safety of Rituxan (rituximab) compared to mycophenolate mofetil, in adults with moderate to severe pemphigus vulgaris, the company said.
Genentech is a member of Switzerland's Roche Group (SIX: RO) (OTCQX: RHHBY).
The study met the primary endpoint at week 52 and demonstrated that Rituxan is superior to MMF, with 40.3% of patients treated with Rituxan achieving sustained complete remission without the use of steroids for 16 consecutive weeks or more, compared to 9.5% in the MMF arm (p
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Article Type:||Clinical report|
|Date:||Oct 23, 2019|
|Previous Article:||Hall Named Chief Operating Officer at Abzena.|
|Next Article:||BioInvent signs production agreement with Cancer Research UK for HMBD-001.|